Try Calculator
← Back to Compound Library NOOTROPICS

Cerebrolysin

Introduction and Overview

Cerebrolysin is a peptide-based neurotrophic compound that has been studied for decades in Europe and other parts of the world for its effects on brain function, neuronal resilience, and cognitive recovery. Unlike single-target compounds, Cerebrolysin is a complex mixture of low- molecular-weight peptides and free amino acids derived from porcine (pig) brain tissue, designed to mimic the activity of the brain’s natural growth factors. The preparation contains over 100 different oligopeptides (approximately 20% neuropeptides and 80% amino acids by weight) that work together as a neurotrophic peptide complex. All peptide components have a molecular weight under 10 kDa, which allows them to cross the blood-brain barrier—a critical requirement for any compound targeting the central nervous system. This distinguishes Cerebrolysin from natural neurotrophic factors such as BDNF, NGF, and GDNF, which cannot cross this barrier and must be administered invasively. Rather than acting as a stimulant or masking symptoms, Cerebrolysin has been studied for how it supports the brain’s own repair, adaptation, and signaling processes at a cellular level. Its unique composition sets it apart: the peptide fragments mimic the activity of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF)—the signaling molecules the brain uses to grow, repair, and maintain neurons. Cerebrolysin was developed in Austria in 1949 and is manufactured by EVER Neuro Pharma. It is approved for medical use in over 45 countries across Europe, Asia, and Russia, where it is prescribed for stroke recovery, traumatic brain injury, dementia, and Alzheimer’s disease. However, it is not FDA-approved in the United States, and some large clinical trials have produced mixed results regarding its benefits for acute stroke treatment.

Quick Reference

Property Detail Drug Class Neurotrophic peptide complex (multicomponent biological preparation) Composition ~20% neuropeptides, ~80% free amino acids; over 100 oligopeptides Source Porcine (pig) brain tissue, enzymatically processed Molecular Weight All components under 10 kDa Concentration 215.2 mg peptide concentrate per mL Routes Intramuscular (IM), intravenous (IV) infusion; not oral

BBB Penetration Crosses blood-brain barrier due to low molecular weight Primary Targets BDNF, NGF, GDNF, and CNTF pathways Manufacturer EVER Neuro Pharma (Austria) Approvals Approved in 45+ countries; not FDA-approved in the US Formulation Ready-to-use sterile aqueous solution in glass ampoules (1, 2, 5, 10, 20 mL)

How It Works

Cerebrolysin acts through multiple complementary mechanisms that together provide broad neurotrophic and neuroprotective support. This multi-pathway approach is one reason Cerebrolysin is frequently discussed in research settings focused on brain aging, cognitive performance, and recovery.

Neurotrophic Factor Mimicry

The peptide fragments in Cerebrolysin mimic the effects of the brain’s natural growth factors without binding to specific receptors in the same manner as full-length neurotrophic proteins. They interact with pathways associated with BDNF, NGF, GDNF, and CNTF, stimulating the same cellular processes these factors normally trigger. This multi-target approach—mimicking multiple growth factors simultaneously—is a key distinguishing feature of Cerebrolysin compared to single-target compounds. Clinical evidence supports this mechanism: a study by Aleixandre et al. (2016) found that Cerebrolysin increased serum BDNF levels by 300% over 16 weeks in Alzheimer’s patients, and when combined with donepezil, BDNF levels increased by 600%—a synergistic effect suggesting Cerebrolysin amplifies the brain’s endogenous neurotrophic signaling.

Neuroprotection

Cerebrolysin protects neurons from multiple threats that are particularly relevant after stroke, traumatic brain injury, or during neurodegenerative disease progression:

Neuroplasticity Enhancement

Neuroplasticity is central to long-term brain health. Cerebrolysin supports the brain’s ability to reorganize and form new connections by increasing synapse formation, promoting dendritic branching and spine density, supporting axonal sprouting, and enhancing synaptic plasticity. These effects are associated with the brain’s ability to adapt to stress, learn new skills, and maintain function as demands increase with age or lifestyle factors.

Neurogenesis Stimulation

Research shows Cerebrolysin can stimulate the proliferation, differentiation, and migration of neural progenitor cells (stem cells) in the brain. This neurogenesis may contribute to recovery after injury and may slow decline in neurodegenerative conditions. The neurogenic effects are mediated through modulation of the neurotrophic factor (NTF) and sonic hedgehog (Shh) signaling pathways, which regulate neurogenesis, angiogenesis (new blood vessel formation), myelination, and maintenance of the neurovascular unit.

Amyloid Beta Effects

In Alzheimer’s disease models, Cerebrolysin has been shown to decrease amyloid beta production by regulating the processing of amyloid precursor protein (APP). It may also reduce existing amyloid deposits, though direct human evidence for this effect remains limited. These anti-amyloid properties complement Cerebrolysin’s neurotrophic and neuroprotective mechanisms in the context of Alzheimer’s disease treatment.

Benefits

Stroke Recovery

Cerebrolysin has been studied extensively in stroke recovery:

therapy

Important Note: Large trials such as CASTA have produced mixed results for acute stroke treatment. Evidence is stronger for Cerebrolysin as an adjunct to rehabilitation than as a standalone acute stroke treatment.

Traumatic Brain Injury

Alzheimer’s Disease

Vascular Dementia

General Cognitive Support

Additional Applications Under Study

antidepressants

What the Science Shows

Cerebrolysin has extensive clinical research, though the quality of evidence varies and results are mixed for some applications. The following summarizes the most significant trials and reviews.

Alzheimer’s Disease

Study 1: Gauthier et al. – Dementia and Geriatric Cognitive Disorders (2015) Design: Meta-analysis of 6 randomized, double-blind, placebo-controlled clinical trials evaluating 30 mL/day of Cerebrolysin in patients with mild-to-moderate Alzheimer’s disease.

Results: Cerebrolysin was significantly more effective than placebo at 4 weeks for cognitive function (SMD −0.40; p = 0.003) and global clinical change (OR 3.32; p = 0.021). At 6 months, global clinical change remained significant (OR 4.98; p = 0.015). The combined “global benefit” measure was significant at both 4 weeks and 6 months (MW 0.57; p = 0.001). Safety was comparable to placebo. Significance: Provided the most comprehensive evidence that Cerebrolysin has an overall beneficial effect and favorable benefit-risk ratio in mild-to-moderate Alzheimer’s disease. Study 2: Aleixandre et al. – International Journal of Neuropsychopharmacology (2016) Design: Clinical study evaluating the effects of Cerebrolysin alone and in combination with donepezil on serum BDNF levels in Alzheimer’s patients over 16 weeks. Results: Cerebrolysin alone increased serum BDNF levels by approximately 300% over 16 weeks. When combined with donepezil, BDNF levels increased by approximately 600%, demonstrating a synergistic effect. Significance: Provided mechanistic evidence that Cerebrolysin amplifies endogenous neurotrophic signaling and demonstrated synergy with standard Alzheimer’s medications, supporting combination therapy approaches.

Stroke

Study 3: Chang et al. – BMC Neurology (2016) Design: Randomized controlled trial evaluating Cerebrolysin combined with standardized rehabilitation versus rehabilitation alone in patients with severe motor impairment after stroke. Results: The Cerebrolysin plus rehabilitation group demonstrated better motor recovery and greater changes in the corticospinal tract compared to the rehabilitation-only group. Significance: Demonstrated that Cerebrolysin enhances rehabilitation outcomes in stroke recovery, supporting its use as an adjunct to physical therapy rather than a standalone acute treatment. Study 4: Bornstein et al. – Neurological Sciences (2018) Design: Meta-analysis of 9 randomized clinical trials evaluating safety and efficacy of Cerebrolysin in early post-stroke recovery. Results: The analysis found evidence supporting Cerebrolysin’s safety and potential benefits in early post-stroke recovery across multiple endpoints. Significance: Provided meta-analytic support for Cerebrolysin in stroke recovery, though results were more modest than those seen in Alzheimer’s disease trials. Important Context – CASTA Trial and 2023 Review:

The CASTA trial (Cerebrolysin Acute Stroke Treatment in Asia) enrolled over 1,000 patients but failed to show benefit compared to placebo for composite stroke outcomes. A 2023 review by Rejdak et al. concluded that Cerebrolysin likely provides no benefit for preventing death in acute ischemic stroke and may increase the rate of adverse events requiring hospitalization. These mixed results highlight the difference between acute stroke treatment (where evidence is weak) and post-stroke rehabilitation support (where evidence is more promising).

Vascular Dementia

Study 5: Chen et al. – Cochrane Database of Systematic Reviews (2013) Design: Cochrane systematic review of 6 randomized trials evaluating Cerebrolysin for vascular dementia. Results: Cerebrolysin improved clinical symptoms compared to placebo. Benefits were observed for global function and cognitive measures. Significance: Provided Cochrane-level evidence supporting Cerebrolysin for vascular dementia, though the authors noted that more high-quality research is needed.

Traumatic Brain Injury

Study 6: Muresanu et al. – Neurological Sciences (2020) Design: The CAPTAIN II trial evaluating Cerebrolysin in moderate-to-severe traumatic brain injury. Results: The trial found improvements in neurorecovery measures in patients receiving Cerebrolysin compared to controls. Significance: Provided clinical trial evidence supporting Cerebrolysin for TBI recovery, with benefits observed for both cognitive and physical function.

Safety Data

Study 7: Thome and Doppler – Drugs of Today (2012) Design: Systematic review of safety data from Cerebrolysin clinical trials in dementia and stroke populations. Results: Cerebrolysin was generally well tolerated across multiple trials. Most adverse events were mild and temporary. The safety profile was comparable to placebo in controlled studies. Significance: Confirmed Cerebrolysin’s favorable safety profile after decades of clinical use, supporting its tolerability across multiple indications. Important Context: The evidence base is mixed. For stroke, acute use has not proven beneficial in large trials. For dementia and TBI, smaller trials show promise. A portion of the research comes from European and Asian investigators with financial ties to the manufacturer. Quality of evidence varies significantly across studies.

Dosing Protocol

Important: Cerebrolysin is not FDA-approved in the United States. The following dosing information is derived from international prescribing guidelines, published clinical trials, and practitioner protocols. Any use should be under the supervision of a qualified healthcare provider.

Understanding Clinical vs. Optimization Dosing

Clinical protocols for stroke and dementia use high doses (10 to 50 mL daily) via intravenous infusion in hospital settings. These are physician-supervised treatments for diagnosed neurological conditions. Health optimization and cognitive support protocols use lower doses administered intramuscularly or subcutaneously, aiming to support brain health rather than treat acute disease.

Intramuscular Administration

Doses up to 5 mL can be injected intramuscularly. This is the maximum single IM dose per prescribing guidelines.

Application Dose Frequency Duration Cognitive support 1–2 mL Daily 40 days Mild cognitive 2–5 mL Daily 21–30 days issues General 5 mL Daily 20–30 days neuroprotection Standard cycling protocol: 20 to 40 days on, followed by 60 to 80 days off. Repeat as directed.

Subcutaneous Administration

Some practitioners use subcutaneous injection for convenience, though intramuscular administration is more commonly documented in clinical literature.

Application Dose Frequency Duration Mild cognitive 1 mL Daily 40 days support Neuroprotection 1–2 mL 1–2 times 8–12 weeks daily

Clinical (IV) Protocols – Reference Only

These are hospital-based protocols requiring physician supervision:

IV administration should only occur under medical supervision. It is not appropriate for home use.

Injection Speed

All routes require slow administration per clinical guidelines:

Ampoule Sizes and Selection

Ampoule Volume Typical Use

Size

1 mL 1.0 mL Single daily dose for mild cognitive support 2 mL 2.0 mL Single daily dose for moderate cognitive support 5 mL 5.0 mL Maximum single IM injection 10 mL 10.0 mL Split into multiple IM sites, or IV use only 20 mL 20.0 mL IV infusion only; requires dilution in at least 100 mL Ampoules are single-use only. Once opened, unused solution must be discarded immediately. Choose ampoule size to match your daily dose to minimize waste.

Preparation for Use

No reconstitution is required. Cerebrolysin comes as a sterile, ready-to-use aqueous solution in sealed glass ampoules.

present.

to 25-gauge, 1 to 1.5 inches).

Side Effects

Cerebrolysin has a favorable safety profile based on decades of clinical use and systematic safety reviews. Most adverse events are mild and temporary.

Common Side Effects

Side Effect Frequency Notes Injection site reactions (pain, Common Slow injection reduces redness, swelling) discomfort; cold compress may help Headache Common Usually mild and transient Dizziness Occasional Usually resolves quickly Fatigue Occasional May occur during initial days of treatment Mild nausea Occasional Typically self-limiting Sensation of heat or flushing Occasional Related to injection speed; slow administration reduces risk

Less Common Side Effects

Rare but Serious

seek medical attention.

Contraindications and Precautions

Do Not Use If You Have:

Use with Caution:

pressure closely.

needed.

Cerebrolysin vs. Other Neuroactive Compounds

Compound Type Mechanism Administration Key Distinction Cerebrolysin Peptide Multi-target IM, IV Broadest mixture neurotrophic neurotrophic factor mimicry coverage; 45+ (BDNF, NGF, country approvals GDNF, CNTF) Cortexin Peptide Similar to IM Lower molecular mixture Cerebrolysin; weight profile; neuroprotective Pinealon originally isolated from

Cortexin

Semax Single BDNF Intranasal Easier to peptide upregulation; administer; ACTH analog narrower mechanism Selank Single GABA Intranasal Primarily peptide modulation; anxiolytic; anxiolytic different clinical profile

Dihexa Oligopeptide HGF/c-Met Oral, transdermal, Most potent activation; SC synaptogenic synaptogenesis compound; research-only BPC-157 Single Growth factor SC More versatile peptide modulation; (whole body); less cytoprotection brain-specific

Cerebrolysin’s unique advantages include its multi-target approach (mimicking multiple growth factors simultaneously), extensive clinical research and use over 75 years, effective blood-brain barrier penetration, and long track record in clinical medicine across 45+ countries. However, it requires injection (unlike intranasal Semax/Selank) and is not FDA-approved (unlike some conventional treatments).

Success Tips

Combine with Rehabilitation

For stroke or TBI recovery, research shows the best results come from combining Cerebrolysin with active rehabilitation. The compound appears to enhance neuroplasticity, making rehabilitation therapy more effective. This finding is supported by the Chang et al. (2016) trial.

Support Brain Health Foundations

Cerebrolysin is not a stimulant, nootropic shortcut, or quick fix. It is best viewed as a foundational neuro-support compound that complements healthy lifestyle practices:

neuroplasticity.

health.

pathways Cerebrolysin supports.

Follow Cycling Protocols

Standard approaches use treatment periods followed by breaks: 20 to 40 days of treatment, then 60 to 80 days off. Repeat as needed. This prevents potential receptor adaptation and allows consolidation of neurotrophic benefits. Some practitioners recommend 2 to 3 cycles per year for maintenance.

Be Patient

Effects develop over days to weeks, not hours. Benefits may continue building throughout the treatment cycle and can persist for weeks to months after stopping. Do not expect immediate stimulant-like effects. Track cognitive markers over time—memory, focus, processing speed, mental clarity—to objectively assess response.

Storage and Handling

Unopened Ampoules:

After Opening:

Visual Inspection: Before each use, verify that the solution is clear (not cloudy), colorless to slightly yellow, free of particles, and in an undamaged ampoule. Do not use if any of these conditions are not met.

Legal Status

United States: Cerebrolysin is not FDA-approved for any indication. It is not classified as a controlled substance and is available as a research compound. Use is considered experimental in the US. International: Cerebrolysin is approved as a prescription medication in over 45 countries, including Austria, Germany, Russia, China, South Korea, and many other European and Asian nations. Approved indications include stroke, traumatic brain injury, dementia, and Alzheimer’s disease. It is manufactured by EVER Neuro Pharma (Austria) and is considered a standard of care for neurological conditions in many countries. Import Considerations: Cerebrolysin can be imported for personal use in some jurisdictions but is not legally marketed in the US. Quality and authenticity of imported products varies. Users should exercise caution and verify the legitimacy of any supplier.

Frequently Asked Questions

How long before I notice effects from Cerebrolysin? Effects typically develop over 1 to 2 weeks. Benefits may continue building throughout the treatment cycle and can persist for weeks to months after stopping. Cerebrolysin is not an immediate-effect compound. Is Cerebrolysin better than Semax for cognitive enhancement? They work through different mechanisms. Cerebrolysin provides broader neurotrophic support by mimicking multiple growth factors simultaneously. Semax specifically upregulates BDNF and is easier to administer (intranasal). Some practitioners use both at different times. Neither is definitively superior, as the choice depends on individual goals and clinical context.

Can I take Cerebrolysin orally?

No. As a peptide preparation, Cerebrolysin would be broken down and destroyed by stomach acids and digestive enzymes if taken orally. It must be injected (intramuscularly or intravenously) to reach the bloodstream and brain.

Why is Cerebrolysin not FDA-approved?

FDA approval requires specific large-scale trials conducted to FDA standards. The manufacturer has focused on markets where Cerebrolysin is already approved. Mixed results in the large CASTA stroke trial also raised questions. Lack of FDA approval does not necessarily mean a compound is ineffective, but it does mean it has not met US regulatory standards for any specific indication. How often should I do Cerebrolysin cycles? Standard protocols suggest 20- to 40-day treatment cycles followed by 60 to 80 days off. Some practitioners recommend 2 to 3 cycles per year for maintenance. Frequency should match your goals and individual response. Does Cerebrolysin help with normal aging or just disease? Most research focuses on disease states (stroke, dementia, TBI). Limited data exists on cognitive enhancement in healthy individuals. Animal studies suggest neuroprotective effects against age- related decline, but whether this translates to healthy humans is not firmly established. Can I combine Cerebrolysin with other nootropics? Some practitioners combine it with other compounds. Studies show enhanced BDNF effects when combined with donepezil. Combining with MAO inhibitors requires caution due to potential blood pressure effects. Introduce compounds individually to assess response before combining. Is porcine-derived Cerebrolysin safe if I avoid pork for religious or ethical reasons?

Cerebrolysin is highly purified and does not contain intact proteins. However, some people with religious or ethical concerns about pork products choose to avoid it. If this is a concern, discuss alternative compounds with your healthcare provider.

References

1. Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to- moderate Alzheimer’s disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5–6):332–347. https://pubmed.ncbi.nlm.nih.gov/25832905/ 2. Aleixandre M, et al. Synergistic increase of serum BDNF in Alzheimer patients treated with Cerebrolysin and donepezil. Int J Neuropsychopharmacol. 2016. 3. Chang WH, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurology. 2016;16:31. 4. Bornstein NM, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta- analysis of nine randomized clinical trials. Neurol Sci. 2018. 5. Chen N, Yang M, Guo J, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2013. 6. Muresanu DF, et al. Efficacy and safety of Cerebrolysin in neurorecovery after moderate- severe traumatic brain injury: results from the CAPTAIN II trial. Neurol Sci. 2020. 7. Thome J, Doppler E. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today. 2012. 8. Rejdak K, et al. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: effects of Cerebrolysin. Med Res Rev. 2023. 9. El-Domiaty HF, et al. Safety and efficacy of Cerebrolysin in infants with communication defects due to severe perinatal brain insult. Neuropsychiatr Dis Treat. 2016. 10. EVER Neuro Pharma. Cerebrolysin Prescribing Information and Dosage Recommendations. 2023. 11. Alzheimer’s Drug Discovery Foundation. Cerebrolysin Cognitive Vitality Report. 2016.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch